TriSalus director granted 92,537 stock options

TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 92,537 shares

Grant/Award 1 txn

Insider Stansky Michael P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	92,537	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 92,537 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this stock option vest in three equal annual installments commencing on February 4, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TLSI director Michael Stansky report?

Michael P. Stansky reported an option grant for 92,537 shares. He received a director stock option giving the right to buy 92,537 TriSalus common shares at $4.91 per share, subject to a multi-year vesting schedule tied to continued service.

What are the key terms of Michael Stansky’s TLSI stock options?

The grant covers 92,537 options at a $4.91 exercise price. These are director stock options on TriSalus common stock, awarded at no cost on the grant date, with vesting over time beginning in 2027, conditioned on his ongoing service.

How do Michael Stansky’s TLSI options vest over time?

The options vest in three equal annual installments. Vesting begins on February 4, 2027, and continues on the next two anniversaries, provided Stansky remains in service with TriSalus Life Sciences on each scheduled vesting date.

Is Michael Stansky’s TLSI option ownership direct or indirect?

The Form 4 reports direct ownership of the options. Following the reported grant, 92,537 director stock options are beneficially owned directly, reflecting compensation to Stansky in the form of derivative securities linked to TriSalus common stock.

What transaction code was used for Michael Stansky’s TLSI option grant?

The transaction used code “A” for an acquisition. In Form 4 terminology, this indicates a grant, award, or other acquisition of derivative securities, here representing director stock options awarded as part of his compensation package.

What security type did Michael Stansky acquire in this TLSI filing?

He acquired a derivative security: a director stock option. The option is a right to buy TriSalus common stock, with 92,537 underlying shares and an exercise price of $4.91, vesting over three years starting February 4, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 06:51 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stansky Michael P

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$4.91	02/04/2026		A		92,537		(1)	02/03/2036	Common Stock	92,537	$0	92,537	D

Explanation of Responses:

1. The shares subject to this stock option vest in three equal annual installments commencing on February 4, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Remarks:

	/s/ Michael P. Stansky	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.